User login
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at the 2012 San Antonio Breast Cancer Symposium. The day-by-day conversation introduces new findings and how these experts apply the studies in their oncology practices.
The CONFIRM Trial
Fulvestrant: 250 mg vs. 500 mg
The ATLAS Trial
Tamoxifen: 5 years vs. 10 years
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at the 2012 San Antonio Breast Cancer Symposium. The day-by-day conversation introduces new findings and how these experts apply the studies in their oncology practices.
The CONFIRM Trial
Fulvestrant: 250 mg vs. 500 mg
The ATLAS Trial
Tamoxifen: 5 years vs. 10 years
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at the 2012 San Antonio Breast Cancer Symposium. The day-by-day conversation introduces new findings and how these experts apply the studies in their oncology practices.
The CONFIRM Trial
Fulvestrant: 250 mg vs. 500 mg
The ATLAS Trial
Tamoxifen: 5 years vs. 10 years